Healthcare

    Supporting the pioneers of the world’s first human IVF pregnancy

    $A80 million capital raise for Monash IVF to strengthen its balance sheet to successfully navigate the COVID-19 pandemic, and to pursue identified growth opportunities. 

    Sector Healthcare
    Sub-sector Services
    Location Australia

    Opportunity

    Monash IVF raised $A80 million to enhance balance sheet flexibility to navigate COVID-19, and to pursue identified organic and inorganic growth opportunities in Australia and South East Asia.

    The capital raise was conducted in the context of national restrictions on non-urgent elective surgeries, including IVF, which had materially impacted Monash IVF’s operations and caused widespread equity capital market disruption.

    Macquarie’s long-term relationship with Monash IVF since executing its IPO in 2014 allowed the experienced healthcare and Equity Capital Market teams to develop and execute the fully underwritten proposal within a tight timeframe.


    Approach

    Macquarie Capital was mobilised quickly to support Monash IVF and was able to conduct diligence and conclude preparations to approach investors promptly after receiving Board approval.

    Based on Macquarie Capital’s deep knowledge of the healthcare services sector, and following extensive modelling for the recommencement of elective surgeries post-COVID-19 shut down, Macquarie Capital was able to advise Monash IVF on a complete solution to trade through various revenue scenarios.

    Macquarie Capital has Australia’s largest Equity Capital Market franchise and was able to use its strong recent experience executing balance sheet fortification raisings during the COVID-19 crisis to successfully undertake the raising for Monash IVF.

    Outcome

    Underwriting support was provided over the full offer size, with sub-underwriting generated for the retail portion despite a three week period of market risk and extremely volatile market conditions.

    The Placement and Institutional Entitlement Offer shortfall received strong support from a range of existing and new investors.

    Retail investors and Monash IVF Doctors also participated in the offer, with an oversubscription facility implemented to facilitate additional participation.

    ~154 million shares were issued representing ~65 per cent of existing Monash IVF shares on issue.

    ~90 per cent

    take-up rate from eligible institutional shareholders

    18.6 per cent

    discount to TERP

    Related insights

    Filter0 items

    Filter

    Technology and services

    View results

    No results message:
    Displayed when filters returns no results.

    Service unavailable:
    Displayed when filter service cannot be reached.

    Sorry, this service is currently unavailable.

    Please try again later.